Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 12/20 | 0.66 |
| ▸ | CA12 | O43570 | 5/20 | 0.66 |
| ▸ | RPA1 | P27694 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MARS1 | P56192 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28195524 | 0.83 | ALPL (0.71) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL3447352 | 0.79 | ALPL (1.00) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL2658851 | 0.77 | ALPL (0.73) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL726574 | 0.77 | TP53 (1.00) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL16701162 | 0.76 | ALPL (0.70) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL4384447 | 0.76 | ALPL (0.64) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL23803931 | 0.76 | ALPL (0.73) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL27758228 | 0.76 | TP53 (0.71) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL23780339 | 0.74 | TP53 (0.64) | ALPLCA12RPA1TP53CA9 | |
| SCHEMBL222852 | 0.74 | TP53 (0.74) | ALPLCA12RPA1TP53CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649009-B2 | N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis | MERCK & CO., INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1765335-B1 | PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20070203186-A1 | Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203186-A1 | Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use | AADAC, GOT2, GLS2 | ALPL 2257/4885CA12 3231/4885RPA1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.